| Identification | Back Directory | [Name]
2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-(2,2-dimethyl-1-propoxypropyl)-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)- | [CAS]
1110767-45-7 | [Synonyms]
Butyzamide
(E)-3-(2,6-Dichloro-4-((4-(3-(2,2-dimethyl-1-pr opoxypropyl)-2-methoxyphenyl)thiazol-2-yl)car bamoyl)phenyl)-2-methylacrylic acid
(E)-3-[2,6-dichloro-4-[[[4-[3-(2,2-dimethyl-1-propoxypropyl)-2-methoxyphenyl]-2-thiazolyl]amino]-oxomethyl]phenyl]-2-methyl-2-propenoic acid
2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-(2,2-dimethyl-1-propoxypropyl)-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)- | [Molecular Formula]
C29H32Cl2N2O5S | [MOL File]
1110767-45-7.mol | [Molecular Weight]
591.55 |
| Hazard Information | Back Directory | [Uses]
Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of human platelets in mouse xenotransplantation assay[1]. | [in vivo]
Butyzamide (10 mg/kg, 50 mg/kg; p.o.; once daily for 20 days) increases human platelets in NOG mice transplanted with human fetal liver-derived CD34+ cells[1].
| [IC 50]
JAK2; STAT3; STAT5 | [References]
[1] Nogami W, et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica. 2008 Oct;93(10):1495-504. DOI:10.3324/haematol.12752 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|